Download Free Medical Indian Pharmaceuticals Industry Report by IBEF PowerPoint Presentation

Indian Pharmaceuticals Industry Report by IBEF PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This "Indian Pharmaceuticals Industry Report (June 2020)" is a very good presentation on Indian Pharmaceutical industry prepared by India Brand Equity Fund ( IBEF ) which works under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.

Tags : Indian pharma, Indian Pharmaceuticals Industry, report, India Brand Equity Fund, IBEF

Published on : Jul 19, 2020 | Views : 2327 | Downloads : 9

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

For updated information, please visit www.ibef.org June 2020 PHARMACEUTICALS
Slide 2-

Table of Contents Executive Summary……………….….…….3 Advantage India…………………..….…......4 Market Overview …………….……….…….6 Recent trends and Strategies……...…..…14 Growth Drivers……………………..............18 Opportunities…….……….......………….…28 Useful Information……….......………….….30
Slide 3-

EXECUTIVE SUMMARY Source: 1 FICCI - Trends & Opportunities for Indian Pharma 2018, Pharmexcil, Assocham and RNCOS Indian pharmaceutical industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK1. Leading pharma producer Indian pharmaceutical sector is expected to grow at a CAGR of 22.4 per cent in the near future and medical device market expected to grow US$ 25 billion by 2025. India is the second largest contributor of global biotech and pharmaceutical workforce. The pharmaceutical sector was valued at US$ 33 billion in 2017. Among fastest growing industries of global exports in generics. India’s pharmaceutical export stood at US$ 20.70 Icnoduiantsacfor 20 per cent billion in FY20. One of the highest exports Itnhdcaiarne hsectlor, one of the fastest growing sectors, is expected to cross US$ 372 billion by 2022. Rapidly growing healthcare sector BYy F 25, India’s biotech industry is estimated to increase to US$ 100 billion. Robust growth in Biotech 3 Pharmaceuticals For updated information, please visit www.ibef.org industry
Slide 4-

ADVANTAGE INDIA Low cost of production and R&D boosts efficiency of Indian pharma companies, leading to competitive exports. Indian pharma export reached US$ 20.70 billion in FY20. India’s cost of production is approximately 33 per cent lower than that of the US. India’s ability to manufacture high quality, low priced medicines, presents a huge business opportunity for the domestic industry. Economic prosperity to improve drug affordability. penetration of health to drive expenditure on Increasing insurance medicine. nWcirtehasinig penetration of pharmacies, especially in rural India, OTC drugs will be readily available Increasing private sector investments in R&D and acquisitions are driving the sector’s growth. Between 2008-19, the S&P BSE Healthcare Index has grown at 16.72 per cent. Pishioanrma V 2020’ aimed at making India a global leader in end-to-end drug manufacturing. ADVANTAGE INDIA 4 Pharmaceuticals For updated information, please visit www.ibef.org Note: 2020 revenue forecasts are estimates of McKinsey, API - Active Pharmaceutical Ingredients, F – Forecast, OTC - Over-The-Counter Source: PwC, McKinsey, Pharmaceuticals Exports Promotion Council of India Uudngdeetr 2B020- 21, allocation to the Ministry of Health and Family Welfare is Rs 65,012 crore (US$ 9.30 billion) Ihnis t sector, 100 per cent FDI is allowed under automatic route.
Slide 5-

Pharmaceuticals MARKET OVERVIEW
Slide 6-

STRUCTURE OF PHARMA SECTOR IN INDIA Pharmaceuticals Source: Dun and Bradstreet Active Pharmaceutical Ingredients/ Bulk drugs Formulations Branded Generics Branded Generics Cardiovascular Aianbtei-tDes Gntaesttrinoa-Il Neurological 6 Pharmaceuticals For updated information, please visit www.ibef.org Anfnetci-ti ves Respiratory Pain Gynecology
Slide 7-

EVOLUTION OF INDIAN PHARMACEUTICAL SECTOR Notes: KAM - Key Account Management, CSO - Contract Sales Organisation Source: TechSci Research Indian Patent Act passed in 1970 Several domestic companies start operations Development of production infrastructure Export initiatives taken Increased patent filings by pharma players Likely adoption of newer sales models such as channel management, KAM and CSO The National Pharmaceutical Pricing Policy, 2012 (NPPP-2012) In Union Budget, 2016, FDI increased to 74 per cent in existing pharmaceutical companies and 100 per cent for new projects The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investments. Liberalised market Indian companies increasingly launch operations in foreign countries India a major destination for generic drug manufacturing Approval of Patents (Amendment) Act 2005, which led to adoption of product patents in India 2013: New Drug Pricing Control Order issued by Directorate of Food and Drugs this will reduce the prices of drugs by 80 per cent 2014: 100 per cent FDI allowed in medical device industry. The investment will be routed through automatic route Leading Indian pharma companies are raising funds aggressively to fund acquisition in domestic as well as international market to increase their product portfolios 2015: India has 10,500 manufacturing units and over 3,000 pharma companies National Health Policy Draft 2015 to increase expenditure in health care sector Patent Act Amendment 2015, it includes amendments in Patent Act 2002 1990-2010 7 Pharmaceuticals For updated information, please visit www.ibef.org 2010- 2015 2010 2016 onwards 1970-90
Slide 8-

Important Segments in Indian Pharmaceutical Sector Active Pharmaceutical Ingredients (APIs) Domestic API consumption is expected to reach US$ 18.8 billion by FY221. In April 2019, a high-level task force was constituted to create a roadmap for increasing domestic production of APIs. Currently India imports over 60 per cent of its APIs from other countries. Contract Research and Manufacturing Services (CRAMS) Fragmented market with more than 1,000 players CRAMS industry has posted 48 per cent CAGR between FY15-18 and expected to witness a strong growth over 25 per cent over 2018-21. TovheernGment plans Biosimilar to allocate US$ 70 million for local players to develop Biosimilar. Tomheesdtic market is expected to reach US$ 40 billion by 2030. Augsuostn 2A019, the moving annual turnover (MAT) for biosimilar molecules sold in the domestic market stood at Rs 1,498 crore (US$ 214.31 million). Formulations Largest exporter of formulations in terms of volume, with 14 per cent market share and 12th in terms of export value. Dgitougbrolew-dthi is expected over the next five years Pharmaceutical industry Source: 1 RNCOS, BMI, Datamonitor, Kemwell Biopharma, Chemical Pharmaceutical Generic Association, ICRA Report estimates, pharmanewsprwire.com, DGCI&S 8 Pharmaceuticals For updated information, please visit www.ibef.org Notes: OTC - Over The Counter,* including biologicals
Slide 9-

INDIAN PHARMA MARKET 16.41 17.87 18.12 20.03 0.00 5.00 10.00 15.00 20.00 25.00 2016 2017 2018 2019 Source: Department of Pharmaceuticals, PwC, McKinsey, AIOCD AWACS, , IQVIA, CII India’s domestic pharmaceutical market turnover reached Rs 1.4 lakh crore (US$ 20.03 billion) in 2019, growing 9.8 per cent year-on-year (in Rs) from Rs 129,015 crore (US$ 18.12 billion) in 2018. Mpeenddicininge s in India is projected to grow 9-12 per cent over the next five years, leading India to become one of the top 10 countries in terms of medicine spending. Isntdia’s co of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over others. yTuhreveAda sector in India reached US$ 4.4 billion by 2018 end and grow at 16 per cent CAGR till 2025. In May 2020, the Indian pharmaceutical sales grew 9 per cent y-o-y to Rs 10,342 crore (US$ 1.47 billion). Visakhapatnam port traffic (million tonnes) Annual Turnover of Indian Pharmaceutical Market (US$ billion) Visakhapatnam port traffic (million tonnes) Quarterly Growth in Indian Pharma Market (%) 8.9 7.4 1.4 9.2 9.3 9.7 9.5 7.8 7.9 6.6 11.5 9.5 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 9 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 10-

COMPOSITION OF INDIAN PHARMA MARKET Source: FCCI Indian Pharma Summit, 1KPMG US-India Dynamic June 2018, 2AIOCD 1With 70 per cent of market share (in terms of revenues), generic drugs form the largest segment of the Indian pharmaceutical sector. Over the Counter (OTC) medicines and patented drugs constitute 21 per cent and 9 per cent, respectively Thahree s of generic drugs is expected to continue increasing; domestic generic drug market is expected to reach US$ 27.9 billion in 2020 Dheuier ctomt petence in generic drugs, growth in this market offers a great opportunity for Indian firms Based on moving annual turnover, Anti-Infectives (13.6%), Cardiac (12.4%), Gastro Intestinals (11.5%) had the biggest market share in the Indian pharma market in 2018. gThesht igrowth in sales in 2018 were seen in hormones (14.2%), anti diabetic (12.9%), and respiratory (12%). eDcuermingberD 2019, on moving annual total (MAT) basis, industry growth was at 9.8 per cent, with price growth at 5.3 per cent, new product growth at 2.7 per cent while volume growth at two per cent y-o-y. 0.41 0.91 0.31 0.34 0.35 0.95 1.14 1.27 1.29 1.43 1.61 1.78 2.17 2.34 2.58 Others Vaccines Hormones Ophthal Anti-Neoplastics Gynaecological Neuro / Cns Derma Pain / Analgesics Respiratory Vitamins / Minerals Anti Diabetic Gastro Intestinal Cardiac Anti-Infectives Segment Wise Moving Annual Turnover2 2018 (US$ billion) 10 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 11-

PHARMA EXPORT TO CONTINUE WITNESSING POSITIVE GROWTH 32.1% 18.0% 15.7% 5.6% 6.8% 6.9% 14.9% North America Africa EU ASEAN LAC Middle East Others Note: EU – European Union, ASEAN - Association of Southeast Asian Nations, LAC - Latin America and the Caribbean Source: Department of Commerce India, Department of Pharmaceuticals, India Business News, Global Trade Atlas, KPMG US-India Dynamic June 2018, Pharmexcil Ihnedia is t world’s largest provider of generic medicines; the country’s generic drugs account for 20 per cent of global generic drug exports (in terms of volumes). Indian drugs are exported to more than 200 countries in the world, with the US as the key market. Imndaiacnomphpanies are capitalising on export opportunities in regulated and semi-regulated markets. Pharmaceutical export from India, which include bulk drugs, intermediates, drug formulations, biologicals, Ayush & herbal products and surgical, reached US$ 20.70 billion in FY20. gTghesbt iexport destination for Indian pharma product is the US. In FY19, 32.1 per cent of India’s pharma exports were to the North America, followed by 17.96 per cent to Africa and 15.70 per cent to the European Union. Visakhapatnam port traffic (million tonnes) Major Export Destinations in India’s Pharma Export in FY19 (%) Visakhapatnam port traffic (million tonnes) Pharmaceutical Exports from India (US$ billion) 16.9 11 Pharmaceuticals For updated information, please visit www.ibef.org 16.8 17.3 19.1 20.7 0.0 5.0 10.0 15.0 20.0 25.0 FY16 FY17 FY18 FY19 FY20
Slide 12-

R&D SPENDING IN INDIAN PHARMA 57 146 225 173 72 - 50 100 150 200 250 Torrent Pharma Cadila Healthcare Cipla Lupin Sun Pharma IYn F 20, highest expenditure on Research and Development was done by Lupin, followed by Cipla. hSaurnmPa’s R&D plan includes developing more products through expanded R&D team for global markets, focussing on more complex products across multiple dosage forms and investments in speciality pipeline. nAisonpeBruUdget 2019- 20, Rs 1,900 crore (US$ 269 million) have been set aside for research of the total amount, Rs 62,659 crore (US$ 8.86 billion) have been allocated for Ministry of Health and Family Welfare. Ianndsia pl to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically. R&D Spending by Top Indian Pharma Companies in FY20 (US$ million) 8.7 8.5 8.6 8.4 7.4 7.6 7.9 7.8 8.0 8.2 8.4 8.6 8.8 FY16 FY17 FY18 FY19E FY20E R&D Investment by Indian Pharma Companies* (% of sales) Source: Company websites, CRISIL Research, HDFC Securities 12 Pharmaceuticals For updated information, please visit www.ibef.org Note: *Top 10 companies as per research by HDFC Securities,
Slide 13-

Pharmaceuticals RECENT TRENDS AND STRATEGIES
Slide 14-

Imndaiacnomphpanies spend 8-13 per cent of their total turnover on R&D. Expenditure on R&D is likely to increase due to the introduction of product patents; companies need to develop new drugs to boost sales. 4e7ntper c of top pharmaceutical companies in India are now providing tools for clinical decision support and 33 per cent are providing virtual caregiving support. India’s pharmaceutical export market is thriving due to strong presence in the generics space. Pharmaceutical exports from India stood at US$ 20.70 billion in FY20 and US$ 1.53 billion in April 2020. ShaurnmPa arm enters China market by entering in agreement with China Medical System. ShaurnmaP entered into a global licensing agreement with Hyderabad based CSIR Indian Institute of Chemical Technology. Iyn2M02a0, Jubilant Generics Ltd entered into a non-exclusive licencing agreement with US-based Gilead Sciences Inc to manufacture and sell the potential COVID-19 drug Remdesivir in 127 countries, including India. uInneJ 2020, Syngene International Ltd developed its own ELISA antibody testing kits at its research facility in Bengaluru and tied up with HiMedia Laboratories for manufacturing and distribution of the testing kits. NOTABLE TRENDS IN THE INDIAN PHARMACEUTICALS SECTOR Notes: R&D - Research and Development, Source: Pharmexcil Research and development 14 Pharmaceuticals For updated information, please visit www.ibef.org Increasing exports Expansion by Indian players abroad Joint Ventures
Slide 15-

STATES HOSTING KEY PHARMACEUTICAL VENTURES Source: Company websites Wockhardt's facility covers an area of 40,468 sq meters in Baddi, Himachal Pradesh Baddi is also home to Cipla’s formulations manufacturing facility Piramal’s USFDA-approved manufacturing plant in Hyderabad GlaxoSmithKline has a major facility at Rajahmundry, Andhra Pradesh Mandideep in Madhya Pradesh is the manufacturing hub for Lupin’s cephalosporin and ACE-Inhibitors Cipla has a formulations manufacturing plant at Indore Dholka in Gujarat houses a major manufacturing facility of Cadila, which spans over 100 acres Lupin has an USFDA-approved plant at Tarapur, Maharashtra. The facility forms the core of Lupin's fermentation capabilities Sun Pharma's API manufacturing facility at Toansa, Malanpur, Guwahati, Ankleshwar, Panoli, Ahmednagar, Maduramthakam 15 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 16-

STRATEGIES ADOPTED Source: Company websites, Ministry of External Affairs, RBI 16 Pharmaceuticals For updated information, please visit www.ibef.org Notes: R&D – Research and Development
Slide 17-

Pharmaceuticals GROWTH DRIVERS
Slide 18-

GROWTH DRIVERS OF INDIAN PHARMA SECTOR of Canotsatgaedv aSnkpilloewdemr Ianjodriamaanmufacturing hub for generics Icnoduiantsacfor 22 per cent overall USFDA approved plants Increasing penetration of chemists Increasing fatal diseases Accessibility of drugs to greatly improve Increasing penetration of health insurance Growing number of stress-related diseases due to change in lifestyle Bagenttoesrtdici facilities 18 Pharmaceuticals For updated information, please visit www.ibef.org National Health Policy 2015, which focuses on increasing public expenditure on healthcare segment Reduction in approval time for new facilities Petlaunpsnteows pharmaceutical education and research institutes Exemptions to drugs manufactured through indigenous R&D from price control under NPPP-2012 Notes: BPL - Below Poverty Line, USFDA - United States Food and Drug Administration, NPPP-2012--The National Pharmaceutical Pricing Policy, 2012 Source: Pharmaceutical Export Promotion Council Growth Drivers
Slide 19-

SUPPLY-SIDE DRIVERS OF INDIAN PHARMA SECTOR 19 Pharmaceuticals For updated information, please visit www.ibef.org Notes: CAGR - Compound Annual Growth Rate Source: BMI, India Biz, Nicholas Hall & Company, IQVIA
Slide 20-

DEMAND DRIVERS OF INDIAN PHARMA SECTOR Accessibility Over US$ 200 billion to be spent on medical infrastructure in the next decade. New business models expected to penetrate tier-2 and 3 cities. Over 160,000 hospital beds expected to be added each year in the next decade. India’s generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally. Acceptability Rising levels of education to increase acceptability of pharmaceuticals. Patients to show greater propensity to self-medicate, boosting the OTC market. Acceptance of biologics and preventive medicines to rise. Surge in medical tourism due to increased patient inflow from other countries. Epidemiological factors Patient pool expected to increase over 20 per cent in the next 10 years, mainly due to rise in population. New diseases and lifestyle changes to boost demand. Increasing prevalence of lifestyle diseases. Affordability Rising income could drive 73 million households to the middle class over the next 10 years. Over 650 million people expected to be covered by health insurance by 2020. The Government plans to provide free generic medicines to half the population at an estimated cost of US$ 5.4 billion. Affordable medicines under Pradhan Mantri Bhartiya Janaushdhi Kendra's (PMBJKs) achieved an impressive sale of Rs 100.40 crore (US$ 14.24 million) in first two months of FY21. Demand drivers 20 Pharmaceuticals For updated information, please visit www.ibef.org Note: RSBY - Rashtriya Swasthya Bima Yojna Source: ICRA Report on Indian Pharmaceutical Sector, Pharmaceutical Industry: Developments in India- Deloitte, Mckinsey Pharma Report 2020
Slide 21-

GROWING HEALTH INSURANCE Note: CAGR is up to FY19 Source: IRDA, General Insurance Council Increasing penetration of non-life insurance including health insurance will drive the expansion of healthcare services and pharmaceutical market in India. Adoption of health insurance in the country has been increasing at a fast pace. rGercotss di premium from health insurance reached Rs 516.37 billion (US$ 7.33 billion) in FY20 and contributed 27 per cent to the gross direct premiums of non-life insurance companies in India. Another boost to the sector will be the National Health Protection Scheme under Ayushman Bharat, announced in Union Budget 2018-19. The scheme was launched in September 2018. Gross Direct Premiums of Non-Life Insurers (US$ billion) Visakhapatnam port traffic (million tonnes) Break-up of non-life insurance market in India (FY20) 27% 73% Health Others Total size: US$ 27.09 billion 14.95 19.89 23.38 24.32 27.09 0.00 5.00 10.00 15.00 20.00 25.00 30.00 FY16 FY17 FY18 FY19 FY20 CAGR 16.01% 21 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 22-

FAVOURABLE POLICY MEASURES SUPPORT GROWTH (1/2) 22 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 23-

FAVOURABLE POLICY MEASURES SUPPORT GROWTH (2/2) Source: Livemint, Union Budget to the Ministry of Health and Family Welfare has increased to Rs 65,012 crore (US$ 9.30 Tlohceatiaoln billion). aTthioenaNl Health Mission Scheme is the largest Government funded healthcare programme, which is expected to benefit 7.31 million poor families in the country by providing a cover of up to Rs 5 lakh (US$ 7,314.22) per family per year on floater basis in the impaneled hospitals across India. TovheernGment has allocated Rs 34,115 crore (US$ 4.88 billion) towards the National Health Mission under which rural and urban people will get benefited. Rs 6,400 crore (US$ 915.72 million) has been allocated to health insurance scheme Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). Union Budget 2020-21 BIRAC has been established to promote research & innovation capabilities in India’s biotech industry. The council will provide funding to biotech companies for technology & product development. BIRAC under Small Business Innovation Research Initiative (SBIRI) scheme supports innovations in biotechnology. Biotechnology Industry Research Assistance Council Programme on application of biotechnology for women was done to provide employment, skill development, awareness generation, health improvement & socio-economic upliftment of the women population. Biotechnology Based Programme for Women – Academia mission was launched in June 2017 to boost development of biopharmaceuticals in 23 Pharmaceuticals For updated information, please visit www.ibef.org TndhuesItry India. National Biopharma Mission
Slide 24-

NATIONAL PHARMA POLICY TO BRING GREATER TRANSPARENCY 24 Pharmaceuticals For updated information, please visit www.ibef.org In 2017, the Department of Pharmaceuticals released a draft National Pharmaceutical Policy with the following objectives: Mll ake a essential drugs accessible to masses through affordable prices. PheroIvnidieant pharmaceutical sector with a long term stable policy environment. nMdaiake I self sufficient in end to end domestic drug manufacturing. Maintain world class quality for domestic consumption and exports. Cosreitiavte a p environment for research and development in the pharma sector. policy, the Department of Pharmaceuticals will have control over the National List of Essential Medicines (NLEM), which decides Ahes npewr t the drugs for which the Government of India can control the prices. oInveNmber 2019, Cabinet approved the extension/renewal of the extant Pharmaceuticals Purchase Policy (PPP) with the same terms and conditions while adding one additional product, namely, Alcoholic Hand Disinfectant (AHD) to the existing list of 103 medicines till the final closure/strategic disinvestment of the Pharma CPSUs.
Slide 25-

GOVERNMENT EXPENDITURE IN THE PHARMA SECTOR ON AN UPTREND 23.58 35.07 34.91 41.42 45.96 0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 FY16 FY17 FY18 FY19 FY20 Note: CAGR - Compound Annual Growth Rate, Source: Business Monitor International, Economic Survey 2019-20 Government expenditure on health increased to Rs 3.24 lakh crore (US$ 45.96 billion) in FY20, implying a CAGR of 18 per cent from FY16. eMcehdnicoalolgty park in Vishakhapatnam, Andhra Pradesh has already been set up with an investment of US$ 183.31 million. States like Himachal Pradesh, Gujarat, Telangana and Maharashtra are showing interest for making investments in these parks. Gecehrmnicaanl t subsidiary has services provider TUV Rheinland’s Indian partnered with Andhra Pradesh MedTech Zone (AMTZ) to create an infrastructure for Electro-Magnetic Interference (EMI/EMC) at an investment of US$ 12.64 million over a course of four to five years. AcosnopmericE Survey 2019-20, Government expenditure (as a percentage of GDP) increased to 1.6 per cent in FY20 from 1.2 per cent in FY15 for health. Visakhapatnam port traffic (million tonnes) Government Expenditure on Health in India (US$ billion) 25 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 26-

INVESTMENTS, JVs INFUSING SUPERIOR CAPABILITIES IN INDIAN FIRMS Irnudgisan D & Pharmaceuticals sector has received cumulative FDI worth US$ 16.39 billion between April 2000 and December 2019. Ohever t last three years, pharmaceuticals segment has accounted for more than 70 per cent of M&A deals. Indian pharmaceutical major Cipla Ltd has agreed to buy a 26 per cent stake in AMP Solar Power Systems Pvt Ltd for approximately Rs 12.90 crore (US$ 1.85 million). Healthcare sector witnessed private equity of total US$ 1.1 billion with 27 deals in first half of 2019. 10% 7% 10% 14% 23% 20% 21% 24% 29% 29% 15% 35% 39% 43% 50% 36% 46% 35% 32% 24% 14% 21% 16% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2013 2014 2015 Early Stage - Angel Growth Investments 7% 2016 2017 2018 Early Stage - VC Pipe Investments Visakhapatnam port traffic (million tonnes) PE Investments in Indian Pharma by Deal Type Source: BMI, Business Standard, EY, IQVIA – Winning the Indian Pharmaceutical Market Nov 2018, DPIIT 26 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 27-

Pharmaceuticals OPPORTUNITIES
Slide 28-

For updated information, please visit www.ibef.org Pharmaceuticals 28 OPPORTUNITIES ABOUND IN CLINICAL TRIALS AND HIGH-END DRUGS India is among the leaders in the clinical trial market. Due to a genetically diverse population and availability of skilled doctors, India has the potential to attract huge investments to its clinical trial market. eAbsruoafryF 2019, India was engaged in 3,618 trials in last one year. Clinical trials market Due to population and increasing income levels, demand for high-end drugs is expected to rise. Growing demand could open up the market for production of high-end drugs in India. High-end drugs With 70 per cent of India’s population residing in rural areas, pharma companies have immense opportunities to tap this market. Demand for generic medicines in rural markets has seen a sharp growth. Various companies are investing in the distribution network in rural areas. Penetration in rural market TonhteraCct Research and Manufacturing Services industry (CRAMS) – estimated at US$ 17.27 billion in 2017-18, is expected to reach US$ 20 billion by 2020. Tarhkeetm has more than 1,000 players. CRAMS Source: BMI, Drug Controller General of India
Slide 29-

Pharmaceuticals USEFUL INFORMATION
Slide 30-

INDUSTRY ORGANISATIONS Address: Kalina, Santacruz (E), Mumbai – 400 098 Phone: 91-22-2667 1072 Fax: 91 22 2667 0744 E-mail: ipacentre@ipapharma.org www.ipapharma.org The Indian Pharmaceutical Association Address: 102-B, Poonam Chambers, Dr A.B. Road Worli, Mumbai – 400 018 Phone: 91-22-2494 4624/2497 4308 Fax: 9122 24950723 E-mail: idma1@idmaindia.com www.idma-assn.org Indian Drug Manufacturers' Association Address: Peninsula Chambers, Ground Floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013 Phone: 9122 24918123, 24912486, 66627007 Fax: 9122 24915168 E-mail: indiaoppi@vsnl.com www.indiaoppi.com Organisation of Pharmaceutical Producers of India Address: C-25, Industrial Estate, Sanath Nagar Hyderabad – 500018 Phone: 91 40 23703910/23706718 Fax: 91 40 23704804 E-mail: info@bdmai.org www.bdmai.org 30 Pharmaceuticals For updated information, please visit www.ibef.org Bulk Drug Manufacturers Association
Slide 31-

GLOSSARY 31 Pharmaceuticals For updated information, please visit www.ibef.org CRAMS: Contract Research and Manufacturing Services API: Active Pharmaceutical Ingredients FDI: Foreign Direct Investment GOI: Government of India INR: Indian Rupee US$ : US Dollar BPL: Below Poverty Line RasShBtrYiy:aRSwastha Bima Yojna ESIC: Employees State Insurance Corporation Wherever applicable, numbers have been rounded off to the nearest whole number
Slide 32-

EXCHANGE RATES Exchange Rates (Fiscal Year) Exchange Rates (Calendar Year) Source: Reserve Bank of India, Average for the year 32 Pharmaceuticals For updated information, please visit www.ibef.org
Slide 33-

DISCLAIMER India Brand Equity Foundation (IBEF) engaged TechSci Research to prepare this presentation and the same has been prepared by TechSci Research in consultation with IBEF. All rights reserved. All copyright in this presentation and related works is solely and exclusively owned by IBEF. The same may not be reproduced, wholly or in part in any material form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this presentation), modified or in any manner communicated to any third party except with the written approval of IBEF. This presentation is for information purposes only. While due care has been taken during the compilation of this presentation to ensure that the information is accurate to the best of TechSci Research and IBEF’s knowledge and belief, the content is not to be construed in any manner whatsoever as a substitute for professional advice. TechSci Research and IBEF neither recommend nor endorse any specific products or services that may have been mentioned in this presentation and nor do they assume any liability or responsibility for the outcome of decisions taken as a result of any reliance placed on this presentation. Neither TechSci Research nor IBEF shall be liable for any direct or indirect damages that may arise due to any act or omission on the part of the user due to any reliance placed or guidance taken from any portion of this presentation. 33 Pharmaceuticals For updated information, please visit www.ibef.org

User Presentation
Related Presentations

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 2

By: MattB
Views: 1798

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 2

By: MattB
Views: 2955

EvaluatePharma pharmaceutical industry world review 2019 and outlook 2024

By: MattB
Views: 1912

Consumer-Directed Healthcare

By: MattB
Views: 2236

Medication Therapy Management Part D Programs

By: MattB
Views: 1907

Antimicrobial Stewardship

By: medhelp
Views: 3146

ADVERSE DRUG REACTIONS

By: JenniferDwayne
Views: 2672

Pregnancy Risk Categories - FDA

By: JenniferDwayne
Views: 1953

Quinolones Oxiquinolones Nitrofurans and Antiviral agents

By: drdwayn
Views: 1671

Informatics support for precision medicine

By: drdwayn
Views: 2357

MattB

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

HEALTH A TO Z